Credit Agricole S A Purchases 8,393 Shares of LeMaitre Vascular, Inc. $LMAT

Key Points

• Credit Agricole S A increased its stake in LeMaitre Vascular by 80.1% during the 1st quarter, now holding shares valued at approximately $1.58 million.
• Insider trading activity included CEO George W. Lemaitre selling 100,000 shares worth over $9.35 million, reducing his ownership by 5.47%.
• Recent analyst reports have raised the price target for LeMaitre Vascular shares to $95.00, with an average rating of "Hold" among research analysts.

Credit Agricole S A boosted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 80.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 18,877 shares of the medical instruments supplier's stock after purchasing an additional 8,393 shares during the period. Credit Agricole S A owned approximately 0.08% of LeMaitre Vascular worth $1,584,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Northern Trust Corp lifted its position in LeMaitre Vascular by 5.4% in the first quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier's stock worth $28,993,000 after purchasing an additional 17,748 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of LeMaitre Vascular by 9.9% in the first quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier's stock valued at $23,921,000 after purchasing an additional 25,680 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of LeMaitre Vascular by 0.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier's stock valued at $26,240,000 after purchasing an additional 1,680 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of LeMaitre Vascular by 11.6% in the first quarter. Russell Investments Group Ltd. now owns 264,261 shares of the medical instruments supplier's stock valued at $22,172,000 after purchasing an additional 27,470 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of LeMaitre Vascular by 34.5% in the first quarter. Invesco Ltd. now owns 235,436 shares of the medical instruments supplier's stock valued at $19,753,000 after purchasing an additional 60,438 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a research note on Wednesday, August 6th. Cantor Fitzgerald increased their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $97.60.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 10,815 shares of LeMaitre Vascular stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the sale, the director owned 17,976 shares of the company's stock, valued at approximately $1,660,802.64. The trade was a 37.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the sale, the chief executive officer directly owned 1,727,003 shares of the company's stock, valued at $161,492,050.53. This represents a 5.47% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 120,815 shares of company stock worth $11,280,206. 9.50% of the stock is currently owned by company insiders.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded down $0.41 during mid-day trading on Thursday, hitting $95.27. The company had a trading volume of 130,646 shares, compared to its average volume of 191,649. The firm has a market cap of $2.16 billion, a P/E ratio of 46.25, a PEG ratio of 2.45 and a beta of 0.79. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The business's 50-day simple moving average is $86.86 and its 200-day simple moving average is $86.43.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. The company had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company's revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the business posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. LeMaitre Vascular's dividend payout ratio (DPR) is currently 38.83%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.